ABBVie today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society Virtual Congress 2021, taking place September 17-22 . More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented. “At AbbVie, we are committed to addressing the unmet needs of people living with a …
– ABBVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22 . More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented.
“At AbbVie, we are committed to addressing the unmet needs of people living with a wide range of movement disorders,” said Sebastian Sorsaburu, MD, vice president, global specialty care medical affairs, AbbVie. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”
Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX (onabotulinumtoxinA) in patients with spasticity and cervical dystonia....
Read Full Story: https://investingnews.com/news/biotech-investing/abbvie-to-highlight-its-leadership-in-movement-disorders-at-the-international-parkinson-and-movement-disorder-society-virtual-congress-2021/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.